NDA 219304 · Deciphera Pharms
Romvimza
Vimseltinib · Oral · Kinase Inhibitor
NovelPriority reviewCDER novel approval, Feb 14, 2025: To treat symptomatic tenosynovial giant cell tumor for which surgical resection will potentially cause worsening functional limitation or severe morbidity
Last checked: Nov 20, 2026Latest source record: Jun 26, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Feb 14, 2025
Approved uses
2
Original approval plus efficacy supplements
Registered trials
7
1 Phase 3, 2 recruiting
FAERS reports
549
85 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 26, 2026.
ROMVIMZA is indicated for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity. ROMVIMZA is a kinase inhibitor indicated for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity. ( 1 )
Mechanism: Vimseltinib is a kinase inhibitor that inhibits colony-stimulating factor 1 receptor (CSF1R). In vitro, vimseltinib inhibited CSF1R autophosphorylation, signaling induced by CSF1 ligand binding, and proliferation of cells expressing CSF1R.
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 26, 2026 Supplement 2 · Efficacy LetterLabel
- Feb 14, 2025 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterLabelMedication Guide
3 products under this application
- ROMVIMZA · VIMSELTINIB 20MG · CAPSULE, ORAL · Prescription
- ROMVIMZA · VIMSELTINIB 30MG · CAPSULE, ORAL · Prescription
- ROMVIMZA · VIMSELTINIB 14MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Vimseltinib" as an intervention, any sponsor and status, largest first.
- Study of Vimseltinib for Tenosynovial Giant Cell TumorPivotal-lookingActive, not recruiting
Deciphera Pharmaceuticals, LLCIndustry
NCT05059262 · 123 participants · Start Oct 14, 2021 · Primary completion Aug 10, 2023
Drug: Vimseltinib; Placebo · For: Tenosynovial Giant Cell Tumor; Pigmented Villonodular Synovitis; Giant Cell Tumor of Tendon Sheath and 2 more
Sites: Duarte, California; Sacramento, California; Aurora, Colorado · 35 sites in all
- Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell TumorActive, not recruiting
Deciphera Pharmaceuticals, LLCIndustry
NCT03069469 · 120 participants (planned) · Start Feb 16, 2017 · Primary completion Aug 2028
Drug: Vimseltinib · For: Advanced Malignant Neoplasm; Pigmented Villonodular Synovitis; Giant Cell Tumor of Tendon Sheath and 2 more
Sites: Palo Alto, California; Denver, Colorado; Jacksonville, Florida · 24 sites in all
- A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)Recruiting
Deciphera Pharmaceuticals, LLCIndustry
NCT06619561 · 48 participants (planned) · Start Nov 21, 2024 · Primary completion Oct 2029
Drug: Vimseltinib · For: Chronic Graft-Versus-Host Disease (cGVHD)
Sites: Duarte, California; Los Angeles, California; Orange, California · 26 sites in all
Deciphera Pharmaceuticals, LLCIndustry
NCT07539090 · 27 participants · Start Jun 5, 2026 · Primary completion Oct 8, 2026
Drug: Vimseltinib; Combined Oral Contraceptive (COC) (ethinyl estradiol [EE]/levonorgestrel [LNG]) · For: Healthy Participants
Sites: Saint Paul, Minnesota
Deciphera Pharmaceuticals, LLCIndustry
NCT07158411 · 22 participants · Start Nov 20, 2025 · Primary completion Jan 30, 2026
Drug: Vimseltinib; Metformin · For: Healthy Participants
Sites: Overland Park, Kansas
- Evaluate the Effect of Vimseltinib on P-glycoprotein (P-gp) Inhibition in Healthy Male ParticipantsRecruiting
Deciphera Pharmaceuticals, LLCIndustry
NCT07744802 · 20 participants (planned) · Start Oct 8, 2026 · Primary completion Dec 2026
Drug: Vimseltinib; Dabigatran · For: Healthy Male Participants
Sites: Overland Park, Kansas
Deciphera Pharmaceuticals, LLCIndustry
NCT07158398 · 20 participants · Start Oct 31, 2025 · Primary completion Dec 8, 2025
Drug: Vimseltinib; Rosuvastatin · For: Healthy Participants
Sites: Overland Park, Kansas
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue136
- swelling face69
- pruritus63
- periorbital swelling60
- peripheral swelling51
- product use issue45
- arthralgia42
- nausea42
- rash42
- eye swelling40
- headache39
- product dose omission issue34
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 2 |
| 2022 | 1 |
| 2025 | 313 |
| 2026 | 233 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Gelderblom H, Bhadri V, Stacchiotti S, et al. · Lancet 2024 · Randomized Controlled Trial, Multicenter Study
- CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib.
Gelderblom H, Razak AA, Taylor MH, et al. · Clin Cancer Res 2024 · Clinical Trial, Phase I, Multicenter Study
- Long-term efficacy, clinical outcomes, and safety of vimseltinib in patients with tenosynovial giant cell tumor: results from the MOTION phase 3 trial.
Bhadri V, Gelderblom H, Stacchiotti S, et al. · Oncologist 2026 · Clinical Trial, Phase III, Randomized Controlled Trial
- Vimseltinib for patients with tenosynovial giant cell tumor: A multicenter, open-label, phase 2 trial.
Stacchiotti S, Blay JY, Rutkowski P, et al. · Cancer 2026 · Multicenter Study, Clinical Trial, Phase II
- A phase I study of the CSF1R inhibitor vimseltinib in combination with the PD-L1 inhibitor avelumab in patients with advanced sarcoma.
Rosenbaum E, Seier K, Bradic M, et al. · ESMO Open 2025 · Clinical Trial, Phase I, Randomized Controlled Trial
- Mixed-Methods to Define Meaningful Change using Exit Interviewand Clinical Trial Data in Patients with Tenosynovial Giant Cell Tumor (TGCT).
Gelhorn HL, Cutts KN, Harrow B, et al. · Qual Life Res 2026 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Deciphera Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.